Shotel Medical

Executive Summary

Shotel Medical is a private medical device company based in San Diego, focused on revolutionizing ankle arthrodesis surgery through its proprietary Shotel technique. The approach aims to enable smaller incisions, faster healing, earlier return to function, and improved quality of life for patients suffering from ankle arthritis or injuries. With a founding year of 2015 and a private status, the company operates in the orthopedic device space, targeting a large addressable market given the prevalence of ankle arthritis and pickleball-related injuries among retirees. While specific financial details are not publicly available, the company's value proposition aligns with growing demand for minimally invasive orthopedic procedures. The company currently has no commercial products or FDA approvals, indicating an early developmental stage. Shotel Medical's technology represents a potential shift in ankle fusion surgery, traditionally performed with open techniques. The Shotel technique may reduce surgical trauma and recovery time, appealing to an aging population active in sports like pickleball. However, the company faces typical early-stage risks including regulatory hurdles, clinical validation, and market adoption. Successful execution could position Shotel as a leader in a niche but growing segment. The company's recent inclusion in biopharmguy databases suggests increased visibility, but further due diligence is needed regarding intellectual property, clinical data, and funding.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Shotel Arthrodesis System35% success
• Q4 2026Publication of Early Clinical Outcomes from Feasibility Study50% success
• Q1 2027Strategic Partnership or Distribution Agreement with Major Orthopedic Company20% success